Successful duloxetine treatment of a binge eating disorder: a case report.
We report the successful treatment of a case of refractory binge eating disorder (BED) with duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, resulting in complete remission of the patient's bingeing behaviours. This case is discussed in the context of the existing literature on the psychopharmacology of BED. Results demonstrate that inhibition of 5-HT and noradrenaline reuptake by duloxetine markedly reduces food intake, suggesting that this may be a novel approach for the treatment of obesity.
Bernardi
S
S
Università degli Studi di Firenze, Firenze, Italy.
Pallanti
S
S
D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D002032:Bulimia / Q000188:drug therapy* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D000068736:Duloxetine Hydrochloride; D004435:Eating / Q000187:drug effects; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use*
D018759:Adrenergic Uptake Inhibitors; D000068736:Duloxetine Hydrochloride; D009638:Norepinephrine; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes